Welcome to our dedicated page for Coya Therapeutics news (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics stock.
Coya Therapeutics, Inc. develops investigational biologics intended to enhance regulatory T-cell, or Treg, function in neurodegenerative disorders. Company news centers on COYA 302, including clinical and regulatory updates in amyotrophic lateral sclerosis and frontotemporal dementia, biomarker publications, and research on systemic inflammation, lipid peroxidation, axonal injury, and Treg dysfunction.
Coya updates also cover its Treg-focused therapeutic platforms, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Recurring business developments include collaboration activity with Dr. Reddy’s Laboratories, milestone-related revenue disclosures, operating results, stockholder communications, and board or governance changes.
Coya Therapeutics (Nasdaq: COYA) entered a definitive securities purchase agreement to sell 2,522,727 shares of common stock at $4.40 per share in a private placement for gross proceeds of approximately $11.1 million, expected to close on or about January 30, 2026.
Investors are Dr. Reddy’s Laboratories ($10.0 million) and Greenlight Capital ($1.1 million). Proceeds will fund tech transfer and scale-up manufacturing for low-dose IL-2 to support commercial readiness of COYA 302. The company will file a resale registration statement with the SEC within 45 days of closing.
Coya Therapeutics (NASDAQ: COYA) issued a letter outlining 2026 priorities focused on advancing COYA 302 in ALS and FTD and progressing COYA 303 in Alzheimer’s disease. The company has initiated the ALSTARS Phase 2 ALS trial with active dosing and U.S. and Canadian sites, and targets full enrollment in H2 2026 with a topline readout in Q1 2027. Coya reported $46.8 million cash as of December 31, 2025, no debt, non-dilutive funding of $8.4 million from Dr. Reddy’s, and a cash runway into H2 2027. Additional translational datasets and a Phase 2a FTD study initiation are planned in 2026.
Coya Therapeutics (NASDAQ: COYA) reported results from a 9-patient, investigator-initiated open-label study of low-dose IL-2 plus CTLA4-Ig in frontotemporal dementia over 22 weeks of dosing. The study observed statistically significant increases in regulatory T-cell (Treg) numbers and suppressive function beginning at two weeks and sustained through week 22. Cognitive measures remained stable: MoCA (baseline 13.5, week 22 14) and CDR-FTLD (baseline 4.8, week 22 5.5) showed no meaningful decline. Safety was tolerable with no serious adverse events and injection-site erythema in 33.3% of participants. Company commented on advancing COYA 302 to a controlled Phase 2 trial.
Coya Therapeutics (NASDAQ: COYA) announced that the U.S. FDA has accepted its IND for COYA 302 to treat frontotemporal dementia (FTD) on January 5, 2026. FTD affects about 60,000 Americans, has an average onset age of 58 and average survival of 7.5 years. The company positions COYA 302 to enhance regulatory T cell (Treg) anti-inflammatory function as a disease‑modifying approach for sporadic FTD. Coya also expects to announce topline results soon from an investigator‑initiated open‑label study evaluating low‑dose IL‑2 and CTLA4‑Ig in mild‑to‑moderate FTD.
Coya Therapeutics (NASDAQ: COYA) announced that Health Canada accepted the Clinical Trial Application for COYA 302 on December 23, 2025, allowing activation of Canadian clinical sites for the ALSTARS phase 2 placebo‑controlled trial in amyotrophic lateral sclerosis (ALS).
The CTA acceptance permits patient enrollment at Canadian ALS centers, expanding recruitment alongside ongoing U.S. sites and enabling broader site activation and patient access for the study.
Coya Therapeutics (NASDAQ: COYA) announced on December 9, 2025 that dosing of ALS patients has commenced in the Phase 2 ALSTARS Trial of COYA 302.
ALSTARS is a multi-center, randomized, double-blind, placebo-controlled study enrolling patients in the United States and Canada to assess safety and efficacy of COYA 302, a combination of low-dose IL-2 and CTLA-4 Ig designed to boost regulatory T cells and suppress pro-inflammatory myeloid activity in ALS.
The company will receive a $4.2 million milestone payment from strategic partner Dr. Reddy’s Laboratories tied to this dosing milestone.
Coya Therapeutics (NASDAQ: COYA) announced that company management will participate in two investor and scientific conferences on December 2, 2025. CEO Dr. Arun Swaminathan will appear in a fireside chat at the 8th Annual Evercore Healthcare Conference in Miami from 8:45–9:05 am ET with a live webcast available.
CMO Dr. Fred Grossman will join a roundtable at the 18th CTAD Conference in San Diego from 3:10–3:50 pm ET titled “Charting the Path Forward for Combination Therapy in Alzheimer’s Disease.” Webcasts and archived replays will be available on the company’s Investor Relations Events and Presentations page, with replays accessible for 90 days.
ReAlta Life Sciences (AVIR) appointed Howard Berman, Ph.D. as Executive Chairman effective immediately on November 25, 2025. The company said Dr. Berman brings more than 20 years of biopharma leadership across company formation, clinical development, strategic partnerships, and public-market execution.
ReAlta highlighted pegtarazimod's clinical data and safety profile across three life-threatening diseases and said the peptide platform targets complement and neutrophil-driven inflammation. Dr. Berman currently chairs Coya Therapeutics and serves on the board of Atea Pharmaceuticals.
Coya Therapeutics (NASDAQ: COYA) launched the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled 24-week study of COYA 302 in patients with amyotrophic lateral sclerosis (ALS) (ClinicalTrials.gov: NCT 07161999).
The study will enroll 120 participants across approximately 25 centers in the United States and Canada. Participants completing the 24-week placebo-controlled phase may join a 24-week blinded extension during which all participants will receive COYA 302 at one of two prespecified doses. Study details and eligibility are available on the trial registry. The trial will be presented on September 29, 2025 during a NEALS educational webinar.
Coya Therapeutics (NASDAQ: COYA) reported Q3 2025 results and a corporate update: the FDA accepted the IND for COYA 302 in ALS and Coya launched the Phase 2 ALSTARS trial (NEALS-affiliated). The company received a $4.2M milestone from Dr. Reddy’s and closed an upsized public offering of $23.0M, extending cash runway into 2H 2027. Cash and equivalents were $28.1M at September 30, 2025. Q3 collaboration revenue was $3.6M (including $3.3M license revenue on IND acceptance). R&D expenses were $2.9M, G&A $2.6M, and net loss was $2.1M for the quarter.